Invasive Haemophilus influenzae disease. Spain 2024
DOI:
https://doi.org/10.4321/s2173-92772026000200005Keywords:
Invasive disease by Haemophilus influenzae; Haemophilus influenzae; Spain; Epidemiological analysis; 2024Abstract
Introduction: Epidemiological analysis of invasive Haemophilus influenzae disease (IHD) in Spain during 2024 and its comparison with previous years (2015-2023).
Method: Descriptive epidemiological analysis of IHD cases reported to the National Epidemiological Surveillance Network (RENAVE) in 2024. The variables analyzed were: sex, age group, date of onset of symptoms, reporting region, death, clinical manifestation, and serotype.
Results: In 2024, 769 cases of HIE were reported (54% men) with a cumulative incidence rate of 1.58 (number of cases per 100,000 inhabitants). The highest incidence rates in 2024 were observed in children under 1 year of age and in the population aged 85 years and over. Typical seasonal pattern of this disease was observed, with a higher number of cases of HIE in autumn and winter. The most frequent clinical manifestation, regardless of age, was bacteremic pneumonia (49,0% of cases); 83.7% of deaths occurred in the 65-year-old age group. The serotype of most reported cases of HIE is unknown.
Discussion: In 2024, the highest cumulative incidence in the last 10 years was recorded. Improved reporting of microbiological characterization data is crucial for conducting surveillance of this disease and for evaluation of the vaccination program.
Downloads
References
Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Red Nacional de Vigilancia Epidemiológica. Protocolos de la Red Nacional de Vigilancia Epidemiológica. Madrid: Instituto de Salud Carlos III; 2013. [Cited 2026 Jan 20]. Available from: https://cne.isciii.es/documents/d/cne/protocolo-de-vigilancia-de-enfermedad-invasora-por-haemophilus-influenzae-pdf
Limia Sánchez A, Olmedo Lucerón C, Soler Soneira M, Cantero Gudino E, Sánchez-Cambronero Cejudo L. Ponencia de Programa y Registro de Vacunaciones y evolución del calendario de vacunación en España. Rev Esp Salud Publica. 2020;94: e202003018.
Ministerio de Sanidad. Calendario común de vacunación a lo largo de toda la vida. Calendario recomendado año 2026 [Internet]. Madrid: Ministerio de Sanidad; 2026. Available from: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/calendario/docs/CalendarioVacunacion_Todalavida.pdf
Ministerio de Sanidad. Vacunación específica en personas adultas (≥18 años) con condiciones de riesgo [Internet]. Madrid: Ministerio de Sanidad; 2026. Available from: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/calendario/docs/CalendarioVacunacion_GRadultos.pdf
Ministerio de Sanidad. Vacunación específica en menores y adolescentes (<18 años) con condiciones de riesgo. Calendario recomendado año 2026 [Internet]. Madrid: Ministerio de Sanidad; 2026. Available from: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/calendario/docs/CalendarioVacunacion_GRinfantil.pdf
European Centre for Disease Prevention and Control. TESSy metadata report [Internet].Stockholm: ECDC. Available from: https://www.ecdc.europa.eu/en/publications-data/tessy-metadata-report
European Parliament, Council of the European Union. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation). Off J Eur Union. 2016;59(L119):1-88.
España. Ley Orgánica 3/2018, de 5 de diciembre, de Protección de Datos Personales y garantía de los derechos digitales. Boletín Oficial del Estado. 2018 Dec 6;(294): 119788-857.
Instituto de Salud Carlos III. Vigilancia de Infección Respiratoria Aguda: gripe, COVID-19 y VRS. Semana 02/2026 (del 5 de enero al 11 de enero de 2026). Madrid: Instituto de Salud Carlos III; 2026. [Cited 2026 Jan 20]. Available from: https://repisalud.isciii.es/entities/publication/5287ed3c-1b36-4173-9145-97adc5c3a17e
Soler-Soneira M, Granero Melcón B, Arroyo Nebreda V, Sastre García M, Amillategui-Dos-Santos R, Cano Portero R. Enfermedad invasiva por Haemophilus influenzae. España 2021-2022. Boletín Epidemiológico Semanal. 2023;31(3):201-214. doi: 10.4321/s2173-92772023000300005
Soler-Soneira M, Granero-Melcón B, Sastre-García M, Bertrán-Pérez-Hickman M, Amillategui-Dos-Santos R, Cano-Portero R. Enfermedad Neumocócica Invasiva en España en 2022. Boletín Epidemiológico Semanal. 2023;31(4):260-273. doi: 10.4321/s2173-92772023000400006
Soler-Soneira M, Muñoz-Martinez L, Alcaide-Jimenez A, Arroyo Nebreda V, Cano Portero R. Enfermedad invasiva por Haemophilus influenzae. España 2023. Boletín Epidemiológico Semanal. 2024;32(3):137-149. doi: 10.4321/s2173-92772024000300004
Editorial. Patterns of respiratory infections after COVID-19. Lancet Respir Med. 2024 Jan;12(1):1 Available from: https://www.sciencedirect.com/science/article/abs/pii/S2213260023004721?via%3Dihub
European Centre for Disease Prevention and Control. Annual Epidemiological Report for 2023: Haemophilus influenzae disease [Internet]. Stockholm: ECDC; 2025. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/HAEINF_AER_2023_Report.pdf
Allonce, J., Ahsan, M., Browne, A., Witherell, R., & Rasnake, M. Changing Landscape of Haemophilus influenzae Meningitis and Implication on Public Health. Case Rep Infect Dis. 2024; 2024: 5571104. Available from: doi.org/10.1155/2024/5571104
Ministerio de Sanidad. Sistema de Información de Vacunaciones (SIVAMIN) [Internet]. Madrid: Ministerio de Sanidad. Available from: https://pestadistico.inteligenciadegestion.sanidad.gob.es/publicoSNS/I/sivamin/sivamin
Kastrin T, Paragi M, Kolman J, Cizman M, Kraigher A, Gubina M. Characterisation of invasive Haemophilus influenzae isolates in Slovenia, 1993–2008. Eur J Clin Microbiol Infect Dis. 2010;29(6):661-668. Available from: https://pubmed.ncbi.nlm.nih.gov/20306323/
Reilly AS, McElligott M, Mac Dermott Casement C, Drew RJ. Haemophilus influenzae type f in the post-Haemophilus influenzae type b vaccination era: a systematic review. J Med Microbiol. 2022;71(10). Available from: https://pubmed.ncbi.nlm.nih.gov/36306238/
Toor J, Echeverria-Londono S, Li X, Abbas K, Carter ED, Clapham HE, et al. Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. eLife. 2021;10: e67635. Available from: https://pubmed.ncbi.nlm.nih.gov/34253291/
Whittaker R, Economopoulou A, Dias JG, Bancroft E, Ramliden M, Celentano LP. Epidemiology of invasive Haemophilus influenzae disease, Europe, 2007–2014. Emerg Infect Dis. 2017 Mar;23(3):396–404. Available from: https://pubmed.ncbi.nlm.nih.gov/28220749/
Georges S, Lepoutre A, Dabernat H, Levy-Bruhl D. Impact of Haemophilus influenzae type b vaccination on the incidence of invasive Haemophilus influenzae disease in France, 15 years after its introduction. Epidemiol Infect. 2013;141(9):1787-1796. Available from: https://pubmed.ncbi.nlm.nih.gov/23425638
Behrouzi A, Vaziri F, Rahimi-Jamnani F, Afrough P, Rahbar M, Satarian F, Siadat SD. Vaccine candidates against nontypeable Haemophilus influenzae:a review. Iran Biomed J.2017;21(2):69-76.
Galgani I, Annaratone M, Casula D, Di Maro G, Janssens M, Tasciotti A, et al. Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae–Moraxella catarrhalis (NTHi–Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study. Respir Res. 2022; 23:114.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Maria de Viarce Torres de Mier, Josefa Masa-Calles, Rosa Cano Portero

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
El material creado por un autor puede ser distribuido, copiado y exhibido por terceros si se hace referencia a la autoría. No se puede obtener ningún beneficio comercial y las obras derivadas tienen que estar bajo los mismos términos de licencia que el trabajo original


